Form 10-QT - Transition reports [Rule 13a-10 or 15d-10]:
SEC Accession No. 0001641172-25-027041
Filing Date
2025-09-10
Accepted
2025-09-10 16:06:11
Documents
68
Period of Report
2025-06-30

Document Format Files

Seq Description Document Type Size
1 10-QT form10-qt.htm   iXBRL 10-QT 921684
2 EX-31.1 ex31-1.htm EX-31.1 19569
3 EX-31.2 ex31-2.htm EX-31.2 19520
4 EX-32.1 ex32-1.htm EX-32.1 10764
  Complete submission text file 0001641172-25-027041.txt   5185000

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE ptix-20250630.xsd EX-101.SCH 42266
6 XBRL CALCULATION FILE ptix-20250630_cal.xml EX-101.CAL 55931
7 XBRL DEFINITION FILE ptix-20250630_def.xml EX-101.DEF 204948
8 XBRL LABEL FILE ptix-20250630_lab.xml EX-101.LAB 343857
9 XBRL PRESENTATION FILE ptix-20250630_pre.xml EX-101.PRE 279801
70 EXTRACTED XBRL INSTANCE DOCUMENT form10-qt_htm.xml XML 688663
Mailing Address 149 FIFTH AVENUE SUITE 500 NEW YORK NY 10010
Business Address 149 FIFTH AVENUE SUITE 500 NEW YORK NY 10010 (212) 994-8200
Protagenic Therapeutics, Inc.\new (Filer) CIK: 0001022899 (see all company filings)

EIN.: 061390025 | State of Incorp.: DE | Fiscal Year End: 0331
Type: 10-QT | Act: 34 | File No.: 001-12555 | Film No.: 251305941
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)